StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
William Blair Reiterates Outperform Rating on Abbvie (ABBV)
July 26, 2024 5:37 AM
William Blair analyst Tim Lugo reiterated an Outperform rating on Abbvie (NYSE: ABBV).The analyst comments "Stock thoughts: We believe AbbVie ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Next Articles
Abbvie (ABBV) PT Raised to $200 at Goldman Sachs
July 26, 2024 5:53 AM
Abbvie (ABBV) PT Raised to $200 at Barclays
July 26, 2024 3:34 AM
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
July 26, 2024 2:00 AM
Abbvie (ABBV) PT Raised to $210 at Truist Securities
July 25, 2024 4:12 PM
Abbvie (ABBV) PT Raised to $210 at JPMorgan
July 25, 2024 3:56 PM
Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
July 25, 2024 8:30 AM
AbbVie hikes full-year earnings guidance as Humira sales top estimates
July 25, 2024 7:56 AM
AbbVie (ABBV) Misses Q2 EPS by 5c; offers guidance
July 25, 2024 7:50 AM
Form 8-K AbbVie Inc. For: Jul 25
July 25, 2024 7:42 AM
AbbVie lifts 2024 profit forecast, shares hit record high
July 25, 2024 7:39 AM
AbbVie Reports Second-Quarter 2024 Financial Results
July 25, 2024 7:36 AM
Stocks expected to have increasing option volume: ABBV TRU HAS KDP LUV WH IBM CMG NOW LVS
July 25, 2024 5:17 AM
AbbVie (ABBV) call put ratio 1 call to 1 put into quarter results
July 24, 2024 11:21 AM
